BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 15621288)

  • 21. [Insulino-mimetic effects of bis (alpha-furancarboxylato) oxovanadium (IV) in vitro].
    Li YR; Gao LH; Ma YL; Niu YF; Liu WP; Li L
    Yao Xue Xue Bao; 2008 Mar; 43(3):318-22. PubMed ID: 18630272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, characterization and antidiabetic properties of N(1)-2,4-dihydroxybenzylidene-N(4)-2-hydroxybenzylidene-S-methyl-thiosemicarbazidato-oxovanadium(IV).
    Yanardag R; Demirci TB; Ulküseven B; Bolkent S; Tunali S; Bolkent S
    Eur J Med Chem; 2009 Feb; 44(2):818-26. PubMed ID: 18621448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The antilipolytic action of bis(alpha-furancarboxylato)oxovanadium(IV) in adipocytes.
    Gao L; Niu Y; Liu W; Xie M; Liu X; Chen Z; Li L
    Clin Chim Acta; 2008 Feb; 388(1-2):89-94. PubMed ID: 17991430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-diabetic effects of sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate in streptozotocin-induced diabetic rats.
    Li M; Smee JJ; Ding W; Crans DC
    J Inorg Biochem; 2009 Apr; 103(4):585-9. PubMed ID: 19203797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction.
    Yao J; Battell ML; McNeill JH
    Can J Physiol Pharmacol; 1997 Feb; 75(2):83-90. PubMed ID: 9114928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new salicylic acid-derivatized kojic acid vanadyl complex: synthesis, characterization and anti-diabetic therapeutic potential.
    Wei Y; Zhang C; Zhao P; Yang X; Wang K
    J Inorg Biochem; 2011 Aug; 105(8):1081-5. PubMed ID: 21726771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antidiabetic activity of the orally effective vanadyl-poly (gamma-glutamic acid) complex in streptozotocin(STZ)-induced type 1 diabetic mice.
    Karmaker S; Saha TK; Sakurai H
    J Biomater Appl; 2008 Mar; 22(5):449-64. PubMed ID: 17494957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).
    Willsky GR; Goldfine AB; Kostyniak PJ; McNeill JH; Yang LQ; Khan HR; Crans DC
    J Inorg Biochem; 2001 May; 85(1):33-42. PubMed ID: 11377693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Coordination chemistry and insulin-enhancing behavior of vanadium complexes with maltol C6H6O3 structural isomers.
    Saatchi K; Thompson KH; Patrick BO; Pink M; Yuen VG; McNeill JH; Orvig C
    Inorg Chem; 2005 Apr; 44(8):2689-97. PubMed ID: 15819554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, spectroscopic, structural and thermal characterizations of vanadyl(IV) adenine complex prospective as antidiabetic drug agent.
    El-Megharbel SM; Hamza RZ; Refat MS
    Spectrochim Acta A Mol Biomol Spectrosc; 2015 Jan; 135():850-64. PubMed ID: 25150436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative assessment of cell mechanisms of the antidiabetic action of a new organic derivative of oxovanadium(IV) and vanadyl sulfate].
    Aleeva GN; Kiiasov AP; Burykin IM; Khafiz'ianova RKh
    Eksp Klin Farmakol; 2004; 67(3):42-4. PubMed ID: 15341067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of chronic treatment with Bis(maltolato)oxovanadium (IV) in rat model of non-insulin-dependent-diabetes.
    Shinde UA; Mehta AA; Goyal RK
    Indian J Exp Biol; 2001 Sep; 39(9):864-70. PubMed ID: 11831366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new insulin-enhancing agent: [N,N'-bis(4-hydroxysalicylidene)-o-phenylene-diamine]oxovanadium(IV) and its permeability and cytotoxicity.
    Xie MJ; Li L; Yang XD; Liu WP; Yan SP; Niu YF; Meng ZH
    Eur J Med Chem; 2010 Jun; 45(6):2327-35. PubMed ID: 20207051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of vanadyl sulfate on kidney in experimental diabetes.
    Yanardag R; Bolkent S; Karabulut-Bulan O; Tunali S
    Biol Trace Elem Res; 2003 Oct; 95(1):73-85. PubMed ID: 14555801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Modulation effect of bis (alpha-furancarboxylato) oxovanadium (IV) on blood glucose in diabetic rats].
    Gao LH; Xie MJ; Li L; Liu WP; Li YR; Chen ZH
    Yao Xue Xue Bao; 2005 Jun; 40(6):496-500. PubMed ID: 16144312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bis(alpha-furancarboxylato)oxovanadium(IV) prevents and improves dexamethasone-induced insulin resistance in 3T3-L1 adipocytes.
    Zuo YQ; Liu WP; Niu YF; Tian CF; Xie MJ; Chen XZ; Li L
    J Pharm Pharmacol; 2008 Oct; 60(10):1335-40. PubMed ID: 18812026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of the antidiabetic capacity of the VO(dmpp)2 complex.
    Passadouro M; Metelo AM; Melão AS; Pedro JR; Faneca H; Carvalho E; Castro MM
    J Inorg Biochem; 2010 Sep; 104(9):987-92. PubMed ID: 20627316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective effect of vanadyl sulfate on the pancreas of streptozotocin-induced diabetic rats.
    Bolkent S; Bolkent S; Yanardag R; Tunali S
    Diabetes Res Clin Pract; 2005 Nov; 70(2):103-9. PubMed ID: 16188572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antidiabetic activities of Tecoma stans (L.) Juss. ex Kunth.
    Aguilar-Santamaría L; Ramírez G; Nicasio P; Alegría-Reyes C; Herrera-Arellano A
    J Ethnopharmacol; 2009 Jul; 124(2):284-8. PubMed ID: 19397980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vanadium complexes with mixed O,S anionic ligands derived from maltol: synthesis, characterization, and biological studies.
    Monga V; Thompson KH; Yuen VG; Sharma V; Patrick BO; McNeill JH; Orvig C
    Inorg Chem; 2005 Apr; 44(8):2678-88. PubMed ID: 15819553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.